XTL Biopharmaceuticals Ltd ADR - Asset Resilience Ratio

Latest as of March 2025: 9.03%

XTL Biopharmaceuticals Ltd ADR (XTLB) has an Asset Resilience Ratio of 9.03% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

$772.00K

Cash + Short-term Investments

Total Assets

$8.55 Million

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2003–2024)

This chart shows how XTL Biopharmaceuticals Ltd ADR's Asset Resilience Ratio has changed over time. Check XTLB capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down XTL Biopharmaceuticals Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of XTL Biopharmaceuticals Ltd ADR.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$772.00K	9.03%
Total Liquid Assets	$772.00K	9.03%

Asset Resilience Insights

Limited Liquidity: XTL Biopharmaceuticals Ltd ADR maintains only 9.03% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

XTL Biopharmaceuticals Ltd ADR Industry Peers by Asset Resilience Ratio

Compare XTL Biopharmaceuticals Ltd ADR's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
ALTEOGEN Inc KQ:196170	Biotechnology	55.57%
Apogee Therapeutics, Inc. Common Stock NASDAQ:APGE	Biotechnology	47.01%
Definium Therapeutics, Inc. NASDAQ:DFTX	Biotechnology	34.94%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Galapagos N.V. AS:GLPG	Biotechnology	86.45%
Blue Jet Healthcare Limited NSE:BLUEJET	Biotechnology	13.81%
Inventiva S.A PA:IVA	Biotechnology	52.73%

Annual Asset Resilience Ratio for XTL Biopharmaceuticals Ltd ADR (2003–2024)

The table below shows the annual Asset Resilience Ratio data for XTL Biopharmaceuticals Ltd ADR.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	9.03%	$772.00K	$8.55 Million	-15.91pp
2023-12-31	24.94%	$605.00K	$2.43 Million	-13.93pp
2022-12-31	38.87%	$1.63 Million	$4.19 Million	-8.85pp
2021-12-31	47.72%	$3.16 Million	$6.62 Million	+10.64pp
2020-12-31	37.08%	$2.41 Million	$6.50 Million	+5.56pp
2019-12-31	31.52%	$2.27 Million	$7.21 Million	-25.24pp
2018-12-31	56.76%	$4.87 Million	$8.57 Million	+14.17pp
2017-12-31	42.59%	$2.81 Million	$6.59 Million	+28.87pp
2016-12-31	13.72%	$414.00K	$3.02 Million	+9.01pp
2015-12-31	4.72%	$251.00K	$5.32 Million	-11.23pp
2013-12-31	15.95%	$1.28 Million	$8.02 Million	+1.37pp
2012-12-31	14.58%	$1.62 Million	$11.09 Million	-19.11pp
2011-12-31	33.69%	$1.37 Million	$4.07 Million	+5.61pp
2010-12-31	28.07%	$1.07 Million	$3.80 Million	+26.91pp
2008-12-31	1.17%	$40.00K	$3.43 Million	-73.87pp
2007-12-31	75.03%	$10.60 Million	$14.13 Million	-2.84pp
2006-12-31	77.87%	$20.95 Million	$26.90 Million	+38.31pp
2004-12-31	39.56%	$10.14 Million	$25.62 Million	-33.18pp
2003-12-31	72.74%	$18.08 Million	$24.85 Million	--

pp = percentage points

About XTL Biopharmaceuticals Ltd ADR

NASDAQ:XTLB USA Biotechnology

Market Cap

$23.14 Million

Market Cap Rank

#27344 Global

#5585 in USA

Share Price

$2.45

Change (1 day)

-2.59%

52-Week Range

$0.58 - $3.12

All Time High

$9.80